

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA – Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process, if so, what are they?
No

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
There have been no potential issues identified during the scoping process.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
N/A

Approved by Associate Director (name): Jasdeep Hayre

Date: 31/03/2020